Evidence
Cureus. 2024 Apr 5;16(4):e57654. doi: 10.7759/cureus.57654. eCollection 2024 Apr.
ABSTRACT
Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a single case report described improvement in BPD following the intranasal administration of esketamine. We present a case report of a woman with BPD and TRD who responded to treatment with very low-dose sublingual ketamine. Very low-dose sublingual ketamine may be effective for the treatment of psychiatric disorders such as BPD and/or comorbid TRD.
PMID:38707115 | PMC:PMC11070208 | DOI:10.7759/cureus.57654
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression
🌐 365 Days
VR Related Evidence Matrix
